OLK Jul 2024 21.000 call
| Previous close | 3.7000 |
| Open | 3.7000 |
| Bid | 1.0000 |
| Ask | 6.0000 |
| Strike | 21.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.7000 - 3.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireNotice to attend the Extra General Meeting of Olink Holding AB (publ)
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, June 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company”), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CET on Friday 5 July 2024, in the Company’s facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30
- GlobeNewswire
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platfo
- GlobeNewswire
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and e
